Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer

Table 5 Univariate analysis of the correlation of clinicopathological parameters with overall survival in CRC celecoxib subgroup

	HR	95%CI	P value
Sex, male vs female	0.854	0.329-2.219	0.74
Age in yr, ≤ 60 vs > 60	1.249	0.432-3.609	0.70
Cancer, colon vs rectum	1.034	0.420-2.543	0.94
BMI, > 25 vs ≤ 25	1.328	0.351-5.020	0.71
Tumor differentiation, moderate and poor vs well	7.396	2.749-19.90	0.021
Stage, 3 vs 2	1.075	0.415-2.782	0.88
T stage, T4 vs T2/3	1.389	0.537-3.596	0.50
N stage, N1/2 vs N0	1.075	0.415-2.782	0.88
CEA in ng/mL, > 5 vs ≤ 5	1.934	0.743-5.033	0.21
CA19-9 in m/L, > 37 vs ≤ 37	1.551	0.431-5.575	0.43
CD3 TILs, high vs low	1.02	0.414-2.510	0.97
CD8 TILs, high vs low	2.821	0.774-10.29	0.026
Nuclear IDO1, high vs low	3.023	0.585-15.61	0.041
Cytoplasmic IDO1, high vs low	1.623	0.617-4.267	0.31
Nuclear and cytoplasmic IDO1, high vs low	3.023	0.585-15.61	0.041
COX2, high vs low	1.746	0.672-4.541	0.25
Nuclear IDO1/COX2, IV vs I/II/III	1.885	0.279-12.76	0.38
Cytoplasmic IDO1/COX2, IV vs I/II/III	2.740	0.764-9.831	0.038

BMI: Body mass index; CA: Cancer antigen; CEA: Carcinoembryonic antigen; CI: Confidence interval; COX2: Cyclooxygenase 2; CRC: Colorectal carcinoma; HR: Hazard ratio; IDO1: Indoleamine-2,3-dioxygenase 1; TILs: Tumor infiltrating lymphocytes.